



PATENT

Case Docket No. NEREUS.062A

Date: April 6, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Hayashi, et al.
Appl. No. : 10/632,531
Filed : August 1, 2003
For : DEHYDROPHENYLAHISTINS
AND ANALOGS THEREOF
AND THE SYNTHESIS OF
DEHYDROPHENYLAHISTINS
AND ANALOGS THEREOF
Examiner : Unknown
Group Art Unit : 1614

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

April 6, 2004

(Date)

Marc T. Morley, Reg. No. 52,051

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement.
- (X) A PTO Form 1449 listing twenty-seven (27) references, which are enclosed herewith.
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Marc T. Morley
Registration No. 52,051
Attorney of Record
Customer No. 20,995
(619) 235-8550



INFORMATION DISCLOSURE STATEMENT

Applicant : Hayashi, et al.
App. No. : 10/632,531
Filed : August 1, 2003
For : DEHYDROPHENYLAHISTINS AND
ANALOGS THEREOF AND THE
SYNTHESIS OF
DEHYDROPHENYLAHISTINS AND
ANALOGS THEREOF
Examiner : Unknown
Group Art Unit : 1614

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed is form PTO-1449 listing 27 references that are also enclosed.

This Information Disclosure Statement is being filed before the receipt of a first Office Action on the merits, and presumably no fee is required in accordance with 37 C.F.R. § 1.97(b)(3). If a first Office Action on the merits was mailed before the mailing date of this Statement, the Commissioner is authorized to charge the fee set forth in 37 C.F.R. § 1.17(p) to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 4/6/04

By: Marc T. Morley
Marc T. Morley
Registration No. 52,051
Attorney of Record
Customer No. 20,995
(619) 235-8550

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
NEREUS.062AAPPLICATION NO.
10/632,531INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Hayashi, et al.FILING DATE
August 1, 2003GROUP
1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	1.	GB1341375	12/19/73	Great Britain				
	2.	WO 95/21832	08/17/95	PCT				
	3.	WO/0153290	07/26/01	PCT				

EXAMINER
INITIAL

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)

	4.	Ali M. et al. "Toxicity of echinulin from <i>Aspergillus chevalieri</i> in rabbits." <i>Toxicology Letters</i> . 48, 235-41 (1989).
	5.	Burk et al. "Highly Enantioselective Hydrogenation of β -Keto Esters under Mild Conditions." <i>J. Am. Chem. Soc.</i> 117, 4423-4424 (1995).
	6.	Cui, C. et al. "Novel Mammalian Cell Cycle Inhibitors, Tryprostatins A, B and Other Diketopiperazines Produced by <i>Aspergillus fumigatus</i> ." <i>J. Antibiotics</i> . 49, 534-40 (1996).
	7.	Cui, C. et al. "Novel Mammalian Cell Cycle Inhibitors, Tryprostatins A, B and Other Diketopiperazines Produced by <i>Aspergillus fumigatus</i> ." <i>J. Antibiotics</i> . 49, 527-33 (1996).
	8.	Goldani, L.Z. & Sugar, A.M. "Treatment of murine pulmonary mucormycosis with SCH 42427, a broad-spectrum triazole antifungal drug." <i>J Antimicrob Chemother.</i> 33, 369-372 (1994).
	9.	Hamel, E. "Antimitotic Natural Products and Their Interactions with Tubulin." <i>Med. Res. Rev.</i> 16(2), 207-31 (1996).
	10.	Hartwell, L.H. et al. "Checkpoints: Controls that Ensure the Order of Cell Cycle Events." <i>Science</i> , 246, 629-34 (1989).
	11.	Hayashi et al. "Total Synthesis of Anti-microtubule Diketopiperazine Derivatives: Phenylahistin and Aurantiamine." <i>J. Org. Chem.</i> 65, 8402-8405 (2000).
	12.	Horak R.M. et al. "Structures of the Austalides A-E, Five Novel Toxic Metabolites from <i>Aspergillus ustus</i> ." <i>J.C.S. Chem. Comm.</i> 1265-67 (1981).
	13.	Iwasaki, S. "Antimitotic Agents: Chemistry and Recognition of Tubulin Molecule." <i>Med Res Rev.</i> 13, 183-198 (1993).
	14.	Kondoh, M. et al. "Effects of Tryprostatin Derivatives on Microtubule Assembly In Viro and In Situ." <i>J. Antibiotics</i> . 51, 801-04 (1998).

EXAMINER

DATE CONSIDERED

*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
NEREUS.062AAPPLICATION NO.
10/632,531INFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(USE SEVERAL SHEETS IF NECESSARY)

APPLICANT
Hayashi, et al.FILING DATE
August 1, 2003GROUP
1614

EXAMINER INITIAL	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)	
	15.	Kupchan, S.M. et al. "Steganacin and Steganangin, Novel Antileukemic Lignan Lactones from Steganotaenia araliacea 1-3." <i>J. Am. Chem. Soc.</i> 95(4), 1335-36 (1973).
	16.	Loughlin, et al. "Solution-Phase combinatorial synthesis and Evaluation of Piperazine-2,5-dione Derivatives." <i>Bioorg Med Chem Lett.</i> 10, 91-94 (2000).
	17.	Pettit, G.R. et al. "Antineoplastic Agents. 291. Isolation and Synthesis of Combretastatins A-4, A-5, and A-6 1a." <i>J. Med. Chem.</i> 38, 1666-1672 (1995).
	18.	Roberge, M. et al. "Antitumor Drug Fostriecin Inhibits the Mitotic Entry Checkpoint and Protein Phosphatases 1 and 2A." <i>Cancer Res.</i> 54, 6115-21 (1994).
	19.	Sackett, D.L. "Podophyllotoxin, Steganacin and Combretastatin: Natural Products that Bind at the Colchicine Site of Tubulin." <i>Pharmacol. Ther.</i> 59, 163-228 (1993).
	20.	Savu and Katzenellenbogen. "Selective γ Alkylation of copper Enolates Derived from α,β - Unsaturated Acids: Factors Affecting Scope and Regio- and Stereoselectivity." <i>J. Org. Chem.</i> 46, 239-250 (1981).
	21.	Smedsgaard J. et al. "Using direct electrospray mass spectrometry in taxonomy and secondary metabolite profiling of crude fungal extracts." <i>J. Microbiol. Meth.</i> 25, 5-17 (1996).
	22.	Sugar, A., et al. "Comparison of Three Methods of Antifungal Susceptibility Testing with the Proposed NCCLS Standard Broth Macrodilution Assay: Lack of Effect of Phenol Red." <i>Diagn Micro and Infect Diseases.</i> 21, 129-133 (1995).
	23.	Tsacomas et al. "Intramolecular Rearrangements of But-3-enoic Esters." <i>Aust. J. Chem.</i> 53, 435-437 (2000).
	24.	Turner and Rodriguez. "Recent Advances in the Medicinal Chemistry of Antifungal Agents." <i>Current Pharmaceutical Design.</i> 2, 209-224 (1996).
	25.	Usui, T. et al. "Tryprostatin A, a specific and novel inhibitor of microtubule assembly." <i>Biochem J.</i> 333, 543-48 (1998).
	26.	Watanabe et al. 18 th International Congress of Heterocyclic Chemistry in Pacifico Yokohama, Japan (30 July 2001), Abstract, page 255.
	27.	Weisenberg, R.C. et al. "The Colchicine-Binding Protein of Mammalian Brain and its Relation to Microtubules." <i>Biochemistry</i> 7, 4466-79 (1968).

S:\DOCS\MTM\MTM-5817.DOC
030404

EXAMINER	DATE CONSIDERED
<p>*EXAMINER: INITIAL IF CITATION CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED, INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.</p>	